Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial

A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1500 kcal d...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	British journal of cancer Ročník 95; číslo 6; s. 705 - 709
Hlavní autori:	Michel, P, Adenis, A, Fiore, F Di, Boucher, E, Galais, M P, Dahan, L, Mirabel, X, Hamidou, H, Raoul, J L, Jacob, J H, Hellot, M F, Prod'Homme, S, Paillot, B
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 18.09.2006 Nature Publishing Group
Predmet:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Cancer Research Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - radiotherapy Cisplatin - administration & dosage Cisplatin - adverse effects Clinical Study Combined Modality Therapy - adverse effects Deglutition Disorders - etiology Dose Fractionation, Radiation Drug Resistance Epidemiology Esophageal Neoplasms - drug therapy Esophageal Neoplasms - radiotherapy Female Humans Irinotecan Male Medical sciences Middle Aged Molecular Medicine Neoplasm Staging Oncology Remission Induction Survival Rate Treatment Outcome Tumors induction chemotherapy oesophageal cancer exclusive chemo-radiotherapy Antineoplastic agent Digestive system Enzyme Concurrent DNA topoisomerase Enzyme inhibitor Malignant tumor Radiotherapy oesophageal cancer exclusive chemo-radiotherapy Cisplatin Esophagus Irinotecan Alkylating agent Chemotherapy Isomerases Cancerology Treatment Surgery Phase II trial Platinum II Complexes Cancer
ISSN:	0007-0920, 1532-1827
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1500 kcal day −1 were included. Chemotherapy, with cisplatin 30 mg m −2 and irinotecan 60 mg m −2 , was administered at days 1, 8, 22, 29, and concurrently with radiotherapy at days 43, 50, 64 and 71. Radiotherapy was delivered with 50 or 50.4 Gy in 25 fractions/5 weeks. Forty-three patients were included, 10 stage I, 19 stage II and 14 stage III. Mean age was 59.2 years (range 44–79). A total of 30 out of 43 (69.8%) patients underwent all planned treatment. During induction chemotherapy, 14 severe toxicities of grade 3 or 4 in 10 patients (23.3%) were reported with 57.1% due to haematoxicity. During chemoradiotherapy, 31 severe toxicities of grade 3 or 4 with 64.5% due to haematotoxicity were reported in 18 patients. One toxic death occurred (diarrhoea grade 4). The complete clinical response rate was 58.1% (95% CI: 43.4–72.8%). Overall survival rate at 1 and 2 years was 62.8%, (95% CI, 58.3–77.3%) and 27.9% (95% CI, 13.4–41.3%), respectively. In conclusion, cisplatin–irinotecan–radiotherapy is an active and well-tolerated regimen feasible in out-patients.
AbstractList	A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1,500 kcal day(-1) were included. Chemotherapy, with cisplatin 30 mg m(-2) and irinotecan 60 mg m(-2), was administered at days 1, 8, 22, 29, and concurrently with radiotherapy at days 43, 50, 64 and 71. Radiotherapy was delivered with 50 or 50.4 Gy in 25 fractions/5 weeks. Forty-three patients were included, 10 stage I, 19 stage II and 14 stage III. Mean age was 59.2 years (range 44-79). A total of 30 out of 43 (69.8%) patients underwent all planned treatment. During induction chemotherapy, 14 severe toxicities of grade 3 or 4 in 10 patients (23.3%) were reported with 57.1% due to haematoxicity. During chemoradiotherapy, 31 severe toxicities of grade 3 or 4 with 64.5% due to haematotoxicity were reported in 18 patients. One toxic death occurred (diarrhoea grade 4). The complete clinical response rate was 58.1% (95% CI: 43.4-72.8%). Overall survival rate at 1 and 2 years was 62.8%, (95% CI, 58.3-77.3%) and 27.9% (95% CI, 13.4-41.3%), respectively. In conclusion, cisplatin-irinotecan-radiotherapy is an active and well-tolerated regimen feasible in out-patients. A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1500 kcal day−1 were included. Chemotherapy, with cisplatin 30 mg m−2 and irinotecan 60 mg m−2, was administered at days 1, 8, 22, 29, and concurrently with radiotherapy at days 43, 50, 64 and 71. Radiotherapy was delivered with 50 or 50.4 Gy in 25 fractions/5 weeks. Forty-three patients were included, 10 stage I, 19 stage II and 14 stage III. Mean age was 59.2 years (range 44–79). A total of 30 out of 43 (69.8%) patients underwent all planned treatment. During induction chemotherapy, 14 severe toxicities of grade 3 or 4 in 10 patients (23.3%) were reported with 57.1% due to haematoxicity. During chemoradiotherapy, 31 severe toxicities of grade 3 or 4 with 64.5% due to haematotoxicity were reported in 18 patients. One toxic death occurred (diarrhoea grade 4). The complete clinical response rate was 58.1% (95% CI: 43.4–72.8%). Overall survival rate at 1 and 2 years was 62.8%, (95% CI, 58.3–77.3%) and 27.9% (95% CI, 13.4–41.3%), respectively. In conclusion, cisplatin–irinotecan–radiotherapy is an active and well-tolerated regimen feasible in out-patients. A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1500 kcal day −1 were included. Chemotherapy, with cisplatin 30 mg m −2 and irinotecan 60 mg m −2 , was administered at days 1, 8, 22, 29, and concurrently with radiotherapy at days 43, 50, 64 and 71. Radiotherapy was delivered with 50 or 50.4 Gy in 25 fractions/5 weeks. Forty-three patients were included, 10 stage I, 19 stage II and 14 stage III. Mean age was 59.2 years (range 44–79). A total of 30 out of 43 (69.8%) patients underwent all planned treatment. During induction chemotherapy, 14 severe toxicities of grade 3 or 4 in 10 patients (23.3%) were reported with 57.1% due to haematoxicity. During chemoradiotherapy, 31 severe toxicities of grade 3 or 4 with 64.5% due to haematotoxicity were reported in 18 patients. One toxic death occurred (diarrhoea grade 4). The complete clinical response rate was 58.1% (95% CI: 43.4–72.8%). Overall survival rate at 1 and 2 years was 62.8%, (95% CI, 58.3–77.3%) and 27.9% (95% CI, 13.4–41.3%), respectively. In conclusion, cisplatin–irinotecan–radiotherapy is an active and well-tolerated regimen feasible in out-patients. A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1,500 kcal day(-1) were included. Chemotherapy, with cisplatin 30 mg m(-2) and irinotecan 60 mg m(-2), was administered at days 1, 8, 22, 29, and concurrently with radiotherapy at days 43, 50, 64 and 71. Radiotherapy was delivered with 50 or 50.4 Gy in 25 fractions/5 weeks. Forty-three patients were included, 10 stage I, 19 stage II and 14 stage III. Mean age was 59.2 years (range 44-79). A total of 30 out of 43 (69.8%) patients underwent all planned treatment. During induction chemotherapy, 14 severe toxicities of grade 3 or 4 in 10 patients (23.3%) were reported with 57.1% due to haematoxicity. During chemoradiotherapy, 31 severe toxicities of grade 3 or 4 with 64.5% due to haematotoxicity were reported in 18 patients. One toxic death occurred (diarrhoea grade 4). The complete clinical response rate was 58.1% (95% CI: 43.4-72.8%). Overall survival rate at 1 and 2 years was 62.8%, (95% CI, 58.3-77.3%) and 27.9% (95% CI, 13.4-41.3%), respectively. In conclusion, cisplatin-irinotecan-radiotherapy is an active and well-tolerated regimen feasible in out-patients.A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1,500 kcal day(-1) were included. Chemotherapy, with cisplatin 30 mg m(-2) and irinotecan 60 mg m(-2), was administered at days 1, 8, 22, 29, and concurrently with radiotherapy at days 43, 50, 64 and 71. Radiotherapy was delivered with 50 or 50.4 Gy in 25 fractions/5 weeks. Forty-three patients were included, 10 stage I, 19 stage II and 14 stage III. Mean age was 59.2 years (range 44-79). A total of 30 out of 43 (69.8%) patients underwent all planned treatment. During induction chemotherapy, 14 severe toxicities of grade 3 or 4 in 10 patients (23.3%) were reported with 57.1% due to haematoxicity. During chemoradiotherapy, 31 severe toxicities of grade 3 or 4 with 64.5% due to haematotoxicity were reported in 18 patients. One toxic death occurred (diarrhoea grade 4). The complete clinical response rate was 58.1% (95% CI: 43.4-72.8%). Overall survival rate at 1 and 2 years was 62.8%, (95% CI, 58.3-77.3%) and 27.9% (95% CI, 13.4-41.3%), respectively. In conclusion, cisplatin-irinotecan-radiotherapy is an active and well-tolerated regimen feasible in out-patients. A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1500kcalday super(-1) were included. Chemotherapy, with cisplatin 30mgm super(-2) and irinotecan 60mgm super(-2), was administered at days 1, 8, 22, 29, and concurrently with radiotherapy at days 43, 50, 64 and 71. Radiotherapy was delivered with 50 or 50.4Gy in 25 fractions/5 weeks. Forty-three patients were included, 10 stage I, 19 stage II and 14 stage III. Mean age was 59.2 years (range 44-79). A total of 30 out of 43 (69.8%) patients underwent all planned treatment. During induction chemotherapy, 14 severe toxicities of grade 3 or 4 in 10 patients (23.3%) were reported with 57.1% due to haematoxicity. During chemoradiotherapy, 31 severe toxicities of grade 3 or 4 with 64.5% due to haematotoxicity were reported in 18 patients. One toxic death occurred (diarrhoea grade 4). The complete clinical response rate was 58.1% (95% CI: 43.4-72.8%). Overall survival rate at 1 and 2 years was 62.8%, (95% CI, 58.3-77.3%) and 27.9% (95% CI, 13.4-41.3%), respectively. In conclusion, cisplatin-irinotecan-radiotherapy is an active and well-tolerated regimen feasible in out-patients.British Journal of Cancer (2006) 95, 705-709. doi:10.1038/sj.bjc.6603328 www.bjcancer.com
Author	Mirabel, X Hamidou, H Michel, P Galais, M P Adenis, A Paillot, B Dahan, L Hellot, M F Jacob, J H Fiore, F Di Prod'Homme, S Raoul, J L Boucher, E
Author_xml	– sequence: 1 givenname: P surname: Michel fullname: Michel, P email: pierre.michel@chu-rouen.fr organization: Unité d’oncologie digestive, Service d’Hepato-Gastroenterologie, CHU de Rouen – sequence: 2 givenname: A surname: Adenis fullname: Adenis, A organization: Service d’Oncologie Medicale, Centre Oscar Lambret – sequence: 3 givenname: F Di surname: Fiore fullname: Fiore, F Di organization: Unité d’oncologie digestive, Service d’Hepato-Gastroenterologie, CHU de Rouen – sequence: 4 givenname: E surname: Boucher fullname: Boucher, E organization: Département d’Oncologie Medicale, Centre Regional de Lutte Contre le Cancer, Eugene Marquis – sequence: 5 givenname: M P surname: Galais fullname: Galais, M P organization: Service d’Onclogie Digestive, Centre Regional de Lutte Contre le Cancer, Francois Baclesse – sequence: 6 givenname: L surname: Dahan fullname: Dahan, L organization: Unité d’Oncologie Digestive, Service d’Hepato-Gastroentérologie, CHU Timone – sequence: 7 givenname: X surname: Mirabel fullname: Mirabel, X organization: Service de Radiotherapie, Centre Oscar Lambret – sequence: 8 givenname: H surname: Hamidou fullname: Hamidou, H organization: Service de Radiotherapie Centre Régional de Lutte Contre le Cancer, Henri Becquerel, rue d’Amiens – sequence: 9 givenname: J L surname: Raoul fullname: Raoul, J L organization: Département d’Oncologie Medicale, Centre Regional de Lutte Contre le Cancer, Eugene Marquis – sequence: 10 givenname: J H surname: Jacob fullname: Jacob, J H organization: Service d’Onclogie Digestive, Centre Regional de Lutte Contre le Cancer, Francois Baclesse – sequence: 11 givenname: M F surname: Hellot fullname: Hellot, M F organization: Unité de Biostatistique, CHU de Rouen, 1 rue de Germont – sequence: 12 givenname: S surname: Prod'Homme fullname: Prod'Homme, S organization: Sabrina Prod’homme, Delegation à la Recherche Clinique, CHU de Rouen – sequence: 13 givenname: B surname: Paillot fullname: Paillot, B organization: Unité d’oncologie digestive, Service d’Hepato-Gastroenterologie, CHU de Rouen
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18171905$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16967056$$D View this record in MEDLINE/PubMed
BookMark	eNp9kt-KEzEYxQdZcburt15KENSr6SaTfzNeCFKtFha80euQySRtSprUJOPSO9_Bd_DBfBJTWnd1oV6FkN85fOfLuajOfPC6qp4iOEUQt1dpPe3XasoYxLhpH1QTRHFTo7bhZ9UEQshr2DXwvLpIaV2uHWz5o-ocsY5xSNmk-rnww6iyDR4om7ZOZut_ff9ho_UhayU9MMG5cKMH0O-ACl6NMWqfT9HSDyDKwYa80lFud-DG5lUYM0hjXOq4A9aDoFPYruRSSweKRun4GmxGl60qxjqC8pY0WCzAfD57B3K00j2uHhrpkn5yPC-rL_P3n2cf6-tPHxazt9e1IiV-jZnpKaGcmn06wrhiFGGoSdua3hhMVW8INwTpAVNEtUFcl9WRTiLYMqPwZfXm4Lsd-40e9gNF6cQ22o2MOxGkFf--eLsSy_BNNJhBingxeHU0iOHrqFMWG5uUdk56HcYkWsIJ5hijQr78L8natmSisIDP74HrMEZf1iCapus6wjkr0LO_B7-d-M9PF-DFEZBJSWdiWbxNd1yLOOogLRw5cCqGlKI2Qtks9wUpea0TCIp98URai1I8cSxekU3vyW6dTwmuDoJUQF-qcZfqhOI3qWvxDA
CODEN	BJCAAI
CitedBy_id	crossref_primary_10_1186_s13014_021_01788_4 crossref_primary_10_1111_j_1442_2050_2009_01016_x crossref_primary_10_1007_s00066_010_2137_y crossref_primary_10_1016_j_semradonc_2012_05_008 crossref_primary_10_1007_s00761_010_1827_5 crossref_primary_10_1097_MNM_0000000000001619 crossref_primary_10_3892_ol_2016_4478 crossref_primary_10_1111_j_1442_2050_2010_01164_x crossref_primary_10_1310_hpj4312_970 crossref_primary_10_1016_j_ctrv_2010_04_006 crossref_primary_10_3390_cancers12030607 crossref_primary_10_1007_s10388_011_0255_y crossref_primary_10_1111_j_1572_0241_2007_01437_x crossref_primary_10_1080_0284186X_2017_1307518 crossref_primary_10_1038_s41467_021_24288_1 crossref_primary_10_1038_sj_bjc_6604749 crossref_primary_10_3109_07357907_2015_1108426 crossref_primary_10_1093_oncolo_oyae295 crossref_primary_10_1016_j_dld_2013_10_016 crossref_primary_10_1007_s00104_009_1737_5 crossref_primary_10_1586_14737140_2015_1074041 crossref_primary_10_1002_pbc_24205 crossref_primary_10_1016_j_intimp_2024_112939 crossref_primary_10_1007_s10330_009_0113_8 crossref_primary_10_1002_cncr_25349 crossref_primary_10_1007_s00259_015_3004_y crossref_primary_10_1007_s00280_007_0450_7 crossref_primary_10_1186_s13014_016_0589_7 crossref_primary_10_1016_j_jchirv_2011_03_011 crossref_primary_10_1016_j_jviscsurg_2011_05_008 crossref_primary_10_1186_1471_2407_10_510 crossref_primary_10_3389_fonc_2022_813021 crossref_primary_10_1002_jso_22157 crossref_primary_10_1186_1471_2407_13_413 crossref_primary_10_1016_j_ijrobp_2017_05_050 crossref_primary_10_1016_j_radonc_2009_02_019 crossref_primary_10_1016_j_dld_2012_04_017 crossref_primary_10_1093_jjco_hyq208
Cites_doi	10.3322/canjclin.52.1.23 10.1200/JCO.2005.00.034 10.1016/S0959-8049(01)00353-7 10.1056/NEJM199206113262403 10.1136/gut.23.12.1060 10.1002/(SICI)1097-0142(19961101)78:9<1851::AID-CNCR2>3.0.CO;2-I 10.1001/jama.281.17.1623 10.1200/JCO.1999.17.10.3270 10.1056/NEJMra035010 10.1200/JCO.2004.00.1792 10.1111/j.1349-7006.1997.tb00369.x 10.1200/JCO.2000.18.3.455 10.1038/sj.bjc.6690233 10.1200/jco.2005.23.16_suppl.4017 10.1200/JCO.2003.02.147 10.1200/JCO.2002.20.5.1167 10.1002/(SICI)1097-0142(19990301)85:5<1026::AID-CNCR3>3.0.CO;2-N 10.1097/00000421-198310000-00005 10.1056/NEJMoa053422 10.1002/1097-0142(19900715)66:2<214::AID-CNCR2820660204>3.0.CO;2-Z 10.1002/cncr.10279 10.1002/sim.4780090807 10.1046/j.0953-0673.2003.01722.x
ContentType	Journal Article
Copyright	The Author(s) 2006 2006 INIST-CNRS Copyright Nature Publishing Group Sep 18, 2006 Copyright © 2006 Cancer Research UK 2006 Cancer Research UK
Copyright_xml	– notice: The Author(s) 2006 – notice: 2006 INIST-CNRS – notice: Copyright Nature Publishing Group Sep 18, 2006 – notice: Copyright © 2006 Cancer Research UK 2006 Cancer Research UK
DBID	C6C AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7RV 7TO 7U9 7X7 7XB 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AN0 AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB0 LK8 M0S M1P M7P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 7U7 C1K 5PM
DOI	10.1038/sj.bjc.6603328
DatabaseName	Springer Nature OA Free Journals CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & allied health premium. Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database (Proquest) ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences ProQuest Health & Medical Collection PML(ProQuest Medical Library) Biological Science Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Toxicology Abstracts Environmental Sciences and Pollution Management PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic Toxicology Abstracts Environmental Sciences and Pollution Management
DatabaseTitleList	ProQuest Central Student MEDLINE MEDLINE - Academic Toxicology Abstracts
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
DocumentTitleAlternate	Chemoradiotherapy alone in oesophageal cancer
EISSN	1532-1827
EndPage	709
ExternalDocumentID	PMC2360517 1126003611 16967056 18171905 10_1038_sj_bjc_6603328
Genre	Multicenter Study Clinical Trial, Phase II Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- -Q- .55 0R~ 23N 36B 39C 3V. 4.4 406 53G 5GY 5RE 6J9 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 AANZL AAWTL AAYZH AAZLF ABAKF ABAWZ ABDBF ABLJU ABOCM ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACPRK ACRQY ACUHS ACZOJ ADBBV ADFRT ADHDB AEFQL AEJRE AEMSY AENEX AEVLU AFBBN AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AI. AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMYLF AN0 AOIJS ASPBG AVWKF AXYYD AZFZN B0M BAWUL BBNVY BENPR BHPHI BKEYQ BKKNO BNQBC BPHCQ BVXVI C6C CAG CCPQU COF CS3 DIK DNIVK DPUIP DU5 E3Z EAD EAP EAS EBC EBD EBLON EBS EE. EIOEI EJD EMB EMK EMOBN EPL ESX EX3 F5P FDQFY FEDTE FERAY FIZPM FRJ FSGXE FYUFA GX1 HCIFZ HMCUK HVGLF HYE HZ~ IH2 IWAJR J5H JSO JZLTJ KQ8 M1P M7P NAO NAPCQ NQJWS O9- OK1 P2P PQQKQ PROAC PSQYO Q2X RNT RNTTT ROL RPM SNX SNYQT SOHCF SOJ SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TR2 TUS UDS UKHRP VH1 W2D WH7 WOW X7M ~02 ~8M AAFWJ AASML AATNV AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFFHD AFHIU AHWEU AIGIU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PQGLB .GJ 70F 8WZ A6W AACDK AEXYK AILAN FIGPU IQODW M41 Y6R ZGI CGR CUY CVF ECM EIF NPM 7TO 7U9 7XB 8FE 8FH 8FK AZQEC DWQXO GNUQQ H94 K9. LK8 PKEHL PQEST PQUKI PRINS 7X8 7U7 C1K 5PM
ID	FETCH-LOGICAL-c4328-36fb54575f7056467c65130e488fbff35cbf47f41ed3515ef17e66049a1086fc3
IEDL.DBID	M7P
ISSN	0007-0920
IngestDate	Tue Nov 04 01:48:24 EST 2025 Tue Oct 07 09:56:47 EDT 2025 Sun Nov 09 13:23:28 EST 2025 Mon Oct 06 18:03:01 EDT 2025 Mon Jul 21 06:04:31 EDT 2025 Mon Jul 21 09:14:51 EDT 2025 Sat Nov 29 04:33:40 EST 2025 Tue Nov 18 22:12:38 EST 2025 Fri Feb 21 02:43:22 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	6
Keywords	induction chemotherapy oesophageal cancer exclusive chemo-radiotherapy Antineoplastic agent Digestive system Enzyme Concurrent DNA topoisomerase Enzyme inhibitor Malignant tumor Radiotherapy oesophageal cancer exclusive chemo-radiotherapy Cisplatin Esophagus Irinotecan Alkylating agent Chemotherapy Isomerases Cancerology Treatment Surgery Phase II trial Platinum II Complexes Cancer
Language	English
License	http://www.springer.com/tdm CC BY 4.0 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4328-36fb54575f7056467c65130e488fbff35cbf47f41ed3515ef17e66049a1086fc3
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23
OpenAccessLink	https://pubmed.ncbi.nlm.nih.gov/PMC2360517
PMID	16967056
PQID	229994776
PQPubID	41855
PageCount	5
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_2360517 proquest_miscellaneous_847437331 proquest_miscellaneous_68843250 proquest_journals_229994776 pubmed_primary_16967056 pascalfrancis_primary_18171905 crossref_citationtrail_10_1038_sj_bjc_6603328 crossref_primary_10_1038_sj_bjc_6603328 springer_journals_10_1038_sj_bjc_6603328
PublicationCentury	2000
PublicationDate	20060918
PublicationDateYYYYMMDD	2006-09-18
PublicationDate_xml	– month: 9 year: 2006 text: 20060918 day: 18
PublicationDecade	2000
PublicationPlace	London
PublicationPlace_xml	– name: London – name: Basingstoke – name: England
PublicationTitle	British journal of cancer
PublicationTitleAbbrev	Br J Cancer
PublicationTitleAlternate	Br J Cancer
PublicationYear	2006
Publisher	Nature Publishing Group UK Nature Publishing Group
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group
References	DH Ilson (BF6603328_CR11) 2003; 21 A Herskovic (BF6603328_CR10) 1992; 326 EA Poplin (BF6603328_CR21) 1996; 78 BD Minsky (BF6603328_CR18) 2002; 20 LR Coia (BF6603328_CR5) 2000; 18 AL Ogilvie (BF6603328_CR19) 1982; 23 DG Pfister (BF6603328_CR20) 2006; 24 BF6603328_CR2 M Stahl (BF6603328_CR24) 2005; 23 DR Jones (BF6603328_CR14) 1999; 85 MRB Keighley (BF6603328_CR15) 2003; 18 JJ Geh (BF6603328_CR9) 2002; 38 JS Cooper (BF6603328_CR6) 1999; 281 DH Ilson (BF6603328_CR12) 1999; 17 JF Seitz (BF6603328_CR23) 1990; 66 BF6603328_CR27 MI Koukourakis (BF6603328_CR17) 1999; 19 JA Bonner (BF6603328_CR4) 2006; 354 E Bellisant (BF6603328_CR3) 1996; 9 A Jemal (BF6603328_CR13) 2002; 52 PC Enzinger (BF6603328_CR7) 1999; 26 K Tamura (BF6603328_CR26) 1997; 88 MC Prewett (BF6603328_CR22) 2002; 8 PC Enzinger (BF6603328_CR8) 2003; 349 JA Ajani (BF6603328_CR1) 2002; 94 K Takeda (BF6603328_CR25) 1999; 79 DP Kelsen (BF6603328_CR16) 1983; 6
References_xml	– volume: 52 start-page: 23 year: 2002 ident: BF6603328_CR13 publication-title: CA Cancer J Clin doi: 10.3322/canjclin.52.1.23 – volume: 23 start-page: 2310 year: 2005 ident: BF6603328_CR24 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.00.034 – volume: 38 start-page: 300 year: 2002 ident: BF6603328_CR9 publication-title: Eur J Cancer doi: 10.1016/S0959-8049(01)00353-7 – volume: 326 start-page: 1593 year: 1992 ident: BF6603328_CR10 publication-title: N Engl J Med doi: 10.1056/NEJM199206113262403 – volume: 23 start-page: 1060 year: 1982 ident: BF6603328_CR19 publication-title: Gut doi: 10.1136/gut.23.12.1060 – volume: 78 start-page: 1851 year: 1996 ident: BF6603328_CR21 publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19961101)78:9<1851::AID-CNCR2>3.0.CO;2-I – volume: 281 start-page: 1623 year: 1999 ident: BF6603328_CR6 publication-title: JAMA doi: 10.1001/jama.281.17.1623 – volume: 17 start-page: 3270 year: 1999 ident: BF6603328_CR12 publication-title: J Clin Oncol doi: 10.1200/JCO.1999.17.10.3270 – volume: 349 start-page: 2241 year: 2003 ident: BF6603328_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMra035010 – volume: 24 start-page: 1072 year: 2006 ident: BF6603328_CR20 publication-title: J Clin Oncol doi: 10.1200/JCO.2004.00.1792 – volume: 88 start-page: 218 year: 1997 ident: BF6603328_CR26 publication-title: Jpn J Cancer Res doi: 10.1111/j.1349-7006.1997.tb00369.x – volume: 18 start-page: 455 year: 2000 ident: BF6603328_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.2000.18.3.455 – volume: 26 start-page: 12 issue: Suppl 15 year: 1999 ident: BF6603328_CR7 publication-title: Semin Oncol – ident: BF6603328_CR2 – volume: 19 start-page: 2305 year: 1999 ident: BF6603328_CR17 publication-title: Anticancer Res – volume: 79 start-page: 1462 year: 1999 ident: BF6603328_CR25 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6690233 – ident: BF6603328_CR27 doi: 10.1200/jco.2005.23.16_suppl.4017 – volume: 21 start-page: 2926 year: 2003 ident: BF6603328_CR11 publication-title: J Clin Oncol doi: 10.1200/JCO.2003.02.147 – volume: 20 start-page: 1167 year: 2002 ident: BF6603328_CR18 publication-title: J Clin Oncol doi: 10.1200/JCO.2002.20.5.1167 – volume: 85 start-page: 1026 year: 1999 ident: BF6603328_CR14 publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19990301)85:5<1026::AID-CNCR3>3.0.CO;2-N – volume: 8 start-page: 994 year: 2002 ident: BF6603328_CR22 publication-title: Clin Cancer Res – volume: 6 start-page: 539 year: 1983 ident: BF6603328_CR16 publication-title: Am J Clin Oncol doi: 10.1097/00000421-198310000-00005 – volume: 354 start-page: 567 year: 2006 ident: BF6603328_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa053422 – volume: 66 start-page: 214 year: 1990 ident: BF6603328_CR23 publication-title: Cancer doi: 10.1002/1097-0142(19900715)66:2<214::AID-CNCR2820660204>3.0.CO;2-Z – volume: 94 start-page: 641 year: 2002 ident: BF6603328_CR1 publication-title: Cancer doi: 10.1002/cncr.10279 – volume: 9 start-page: 907 year: 1996 ident: BF6603328_CR3 publication-title: Stat Med doi: 10.1002/sim.4780090807 – volume: 18 start-page: 7 issue: Suppl 3 year: 2003 ident: BF6603328_CR15 publication-title: Aliment Pharmacol Ther doi: 10.1046/j.0953-0673.2003.01722.x
SSID	ssj0009087
Score	2.0615814
Snippet	A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with...
SourceID	pubmedcentral proquest pubmed pascalfrancis crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	705
SubjectTerms	Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Cancer Research Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - radiotherapy Cisplatin - administration & dosage Cisplatin - adverse effects Clinical Study Combined Modality Therapy - adverse effects Deglutition Disorders - etiology Dose Fractionation, Radiation Drug Resistance Epidemiology Esophageal Neoplasms - drug therapy Esophageal Neoplasms - radiotherapy Female Humans Irinotecan Male Medical sciences Middle Aged Molecular Medicine Neoplasm Staging Oncology Remission Induction Survival Rate Treatment Outcome Tumors
Title	Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial
URI	https://link.springer.com/article/10.1038/sj.bjc.6603328 https://www.ncbi.nlm.nih.gov/pubmed/16967056 https://www.proquest.com/docview/229994776 https://www.proquest.com/docview/68843250 https://www.proquest.com/docview/847437331 https://pubmed.ncbi.nlm.nih.gov/PMC2360517
Volume	95
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1532-1827 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: M7P dateStart: 20000101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1532-1827 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 7X7 dateStart: 20000101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1532-1827 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 7RV dateStart: 20000101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1532-1827 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: BENPR dateStart: 20000101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1532-1827 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 8C1 dateStart: 20000101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nj9MwEB2xuwghIb4_wkLxAQku2U3qxHa4IChbsRJU1QpWvUWJY4tUKClNC9q_wy9lxklbCl0uXHzxSHHGL-OJPX4P4HmgkqyfaOHHliTMIsH9TEeZH_DI6DCTsXXXo88_yNFITSbJuKvNabqyylVMdIG6qDXtkR_3MW4mkZTi9eybT6JRdLjaKWjswQGRJHBXuTfecO4GqqXMpN24pB-sOBu5Om6mR_lUHwkRcE5C7L-tSTdmWYPusa2uxa7E8-_6yT8OUd3aNLz1n291G252SSl706LoDlwx1V249rE7dr8HP0ngw12AYDjYGZXPVX6JYyGOh6xiFsFU_zAFyy8Y_l_rlvNpt21WFWyeFWV38-uC0U5wvVywpr2gzcqK1YbEFTDS4aA0wXL-irnKR3KFmTPsaww7PWXD4eAdc8Ij9-Hz8OTT4L3fiTv4OkKX-1zYHLM3BIPEHAzDtRYxrqcGA4rNreWxzm0kbRSagmPOZWwoDU5XlGSkDWU1fwD7VV2ZR8DyMLaZ0IEuAh1hBHMciTHXRuaB0SrywF9Nb6o75nMS4PiauhN4rtJmmiIc0g4OHrxY289azo9LLXtbaNmYq1BiqhV7cLia97QLDk26nnQPnq178aumo5qsMvWySYVS6KU48IBdYoFZBbFS8dCDhy0aNw8XiSCneiC3cLo2IErx7Z6q_OKoxftcEGmbBy9XiN4Me7cLHv_zDQ_hertnlfihegL7i_nSPIWr-vuibOY92JNn59ROpGsVtmoQ9uDg7clofNZzn_MvQmlTTw
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3fb9MwED6NgQAJ8XsQBpsfQOwlWxIntoOEENqoVq2rEBrT3oLj2ForlJSmZeq_wzv_I-f8aCl0vO2BZ59S53L3-Wqfvw_gpSdiGcSKuZGxEmYho65UoXQ9GmrlSx6Z6nr0aY_3--LsLP64Bj_buzC2rbLFxAqos0LZPfK9AHEzDjln70bfXCsaZQ9XWwWNOiqO9OwC_7GVb7sH-HlfBUHnw8n-oduICrgqpIFwKTMpVg04CY5rP8KEYhHiuMZANqkxNFKpCbkJfZ1RXOu18blmDOtoaTWJjKL43GtwHWHctx1k_NPpguPXEzVFp939iwOv5YikYq8c7qZDtYsPotQKv_-2Bt4ZyRI_h6l1NFYVun_3a_5xaFuthZ17_5kX78Pdpugm7-sseQBrOn8IN4-btoJH8MMKmFQXPAg6Z2TbA3N3gO9uOSxkTgwmS3GhM5LOiCpyVXNarbaVeUbGMhs0N9tmxO50F9MJKesL6GSQk0Jb8QhEcpyUsmk3fkOqzk7rej0mOFZq0u2STmf_gFTCKo_h85V4aAPW8yLXT4GkfmQkU57KPBUiQlcckBFVmqeeViJ0wG3DKVENs7sVGPmaVB0GVCTlMMHwS5rwc-D13H5Uc5pcarm1FJ0Lc-FzLCUjBzbbOEsa8CuTeZA5sD0fRdSyR1Ey18W0TJgQ6KXIc4BcYoFVk2Xdor4DT-roX_w4i5l1qgN8KS_mBpYyfXkkH5xX1OkBZZaUzoGdNoMW017tgmf_fMNtuHV4ctxLet3-0SbcrvfnYtcXz2F9Mp7qF3BDfZ8MyvFWBRUEvlx1Vv0CjPqorw
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1fb9MwED-NgSYkxH9GGGx-AMFL1iRObAcJIdRSUW1UewC0t8xxbNFqSkrTMvXr8C34dpzzp6XQ8bYHnn1KnPPd-WLf_X4Azz0RyyBWzI2MpTALGXWlCqXr0VArX_LIVO3RX475cChOT-OTLfjZ9sLYsso2JlaBOiuUPSPvBBg345Bz1jFNVcRJr_928s21BFL2orVl06gt5EgvLvDvrXwz6OFSvwiC_vtP3Q9uQzDgqpAGwqXMpJhB4IQ45gEYMhSLMKZrNGqTGkMjlZqQm9DXGcV9Xxufa8Ywp5aWn8gois-9Btc5RSO2TerdVXVJ7IkartOeBMaB1-JFUtEpx4fpWB3igyi1JPC_7Ye3JrLEpTE1p8ampPfv2s0_LnCrfbF_5z_W6F243STj5F3tPfdgS-f3YedjU27wAH5YYpOq8YOgoia2bDB3R6gHi20hc2LQiYoLnZF0QVSRqxrrarOszDMyldmo6XhbEHsCXsxnpKwb08koJ4W2pBIY4XFSyrrj9DWpKj7tMugpwbFSk8GA9PvdHqkIVx7C5yvR0CPYzotcPwaS-pGRTHkq81SIkbvChoyo0jz1tBKhA25rWolqEN8t8ch5UlUeUJGU4wRNMWlM0YGXS_lJjXVyqeT-mqWuxIXPMcWMHNhrbS5pgmKZLA3OgYPlKEYze0Ulc13My4QJgVqKPAfIJRKYTVk0Luo7sFt7wurlLGZWqQ7wNR9ZClgo9fWRfPS1glQPKLNgdQ68ar1pNe3NKnjyzy88gB10puR4MDzag5v1sV3s-uIpbM-mc_0Mbqjvs1E53a-iBoGzq3aqX_RrsQo
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Induction+cisplatin-irinotecan+followed+by+concurrent+cisplatin-irinotecan+and+radiotherapy+without+surgery+in+oesophageal+cancer%3A+multicenter+phase+II+FFCD+trial&rft.jtitle=British+journal+of+cancer&rft.au=Michel%2C+P&rft.au=Adenis%2C+A&rft.au=Fiore%2C+F+Di&rft.au=Boucher%2C+E&rft.date=2006-09-18&rft.issn=0007-0920&rft.volume=95&rft.issue=6&rft.spage=705&rft.epage=709&rft_id=info:doi/10.1038%2Fsj.bjc.6603328&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon